Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma

Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Nasser, Soumana C. (author)
مؤلفون آخرون: Farah, Roula A. (author), Sabbagh, Racha A. (author), Dina, Pele B. (author), Eid, Toufic A. (author)
التنسيق: article
منشور في: 2011
الوصول للمادة أونلاين:http://hdl.handle.net/10725/2257
http://dx.doi.org/10.2174/157488511795304912
http://www.ingentaconnect.com/content/ben/cdth/2011/00000006/00000002/art00003
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513457849630720
author Nasser, Soumana C.
author2 Farah, Roula A.
Sabbagh, Racha A.
Dina, Pele B.
Eid, Toufic A.
author2_role author
author
author
author
author_facet Nasser, Soumana C.
Farah, Roula A.
Sabbagh, Racha A.
Dina, Pele B.
Eid, Toufic A.
author_role author
dc.creator.none.fl_str_mv Nasser, Soumana C.
Farah, Roula A.
Sabbagh, Racha A.
Dina, Pele B.
Eid, Toufic A.
dc.date.none.fl_str_mv 2011-05-02
2015-10-06T08:59:01Z
2015-10-06T08:59:01Z
2015-10-06
dc.identifier.none.fl_str_mv 1574-8855
http://hdl.handle.net/10725/2257
http://dx.doi.org/10.2174/157488511795304912
A Farah, R., C Nasser, S., A Sabbagh, R., B Dina, P., & A Eid, T. (2011). Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma. Current Drug Therapy, 6(2), 97-99.
http://www.ingentaconnect.com/content/ben/cdth/2011/00000006/00000002/art00003
dc.language.none.fl_str_mv en
dc.relation.none.fl_str_mv Current Drug Therapy
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patient's quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.
eu_rights_str_mv openAccess
format article
id LAURepo_df084a2efe079b994217a03faf9a20ce
identifier_str_mv 1574-8855
A Farah, R., C Nasser, S., A Sabbagh, R., B Dina, P., & A Eid, T. (2011). Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma. Current Drug Therapy, 6(2), 97-99.
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/2257
publishDate 2011
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Palliative Tumor Control by Trabectedin in Pediatric Advanced SarcomaNasser, Soumana C.Farah, Roula A.Sabbagh, Racha A.Dina, Pele B.Eid, Toufic A.Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patient's quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.PublishedN/A2015-10-06T08:59:01Z2015-10-06T08:59:01Z2011-05-022015-10-06Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1574-8855http://hdl.handle.net/10725/2257http://dx.doi.org/10.2174/157488511795304912A Farah, R., C Nasser, S., A Sabbagh, R., B Dina, P., & A Eid, T. (2011). Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma. Current Drug Therapy, 6(2), 97-99.http://www.ingentaconnect.com/content/ben/cdth/2011/00000006/00000002/art00003enCurrent Drug Therapyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/22572016-08-22T08:14:59Z
spellingShingle Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
Nasser, Soumana C.
status_str publishedVersion
title Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
title_full Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
title_fullStr Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
title_full_unstemmed Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
title_short Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
title_sort Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
url http://hdl.handle.net/10725/2257
http://dx.doi.org/10.2174/157488511795304912
http://www.ingentaconnect.com/content/ben/cdth/2011/00000006/00000002/art00003